Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding statin boosted AML response rate

Advani AS et al. Leuk Res. 2018 Apr;67:17-20.

Publish date:: April 22, 2018

Key clinical point: Targeting the cholesterol pathway may be a promising approach in patients with acute myelogenous leukemia (AML).

Major finding: Pravastatin in combination with idarubicin and cytarabine had a 30% response rate in poor risk AML patients.

Study details: Results from the poor-risk cohort (n = 46) in SWOG S0919, a phase 2 study.

Disclosures: The research was supported in part by the National Institutes of Health and Bristol-Myers Squibb. Dr. Advani reported having no financial disclosures but other study authors reported relationships with various pharmaceutical companies.

Source: Advani AS et al. Leuk Res. 2018 Apr;67:17-20.

Read the article.

Citation:

Advani AS et al. Leuk Res. 2018 Apr;67:17-20.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release